LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)

Authors :: Alexandros Stratigos
Ketty Peris
Siyu Li
C. Robert
Claas Ulrich
Martin Kaatz
Nicole Basset-Seguin
Timothy Bowler
Axel Hauschild
Karl D. Lewis
Lisa Licitra
Reinhard Dummer
Michael R. Migden
C. Dutriaux
Aleksandar Sekulic
A. Fernandez-Orland
Oliver Bechter
S. Dalle
Matthew G. Fury
Anne Lynn S. Chang
Source :: Annals of Oncology. 31:S1175-S1176
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Primary (chemistry)
Oncology
business.industry
Cancer research
Locally advanced
Medicine
In patient
Basal cell carcinoma
Hematology
business
medicine.disease
Hedgehog

Full Text Access

Tools